238 related articles for article (PubMed ID: 35088118)
1. Clinical and Radiologic Response of Central Giant Cell Granuloma to Denosumab: A 6-Year Prospective Observational Study.
Rhou YJJ; Wang CJ; Nguyen M; Vanderniet JA; Munns CF; Coleman H; Kim J; Holmes-Walker DJ; Lim L; Girgis CM
Calcif Tissue Int; 2022 Apr; 110(4):464-474. PubMed ID: 35088118
[TBL] [Abstract][Full Text] [Related]
2. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
[TBL] [Abstract][Full Text] [Related]
3. Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre.
Vanderniet JA; Wall CL; Mullins A; London K; Lim L; Hibbert S; Briody J; Padhye B; Poon M; Biggin A; Dalla-Pozza L; Munns CF
Bone; 2022 Jun; 159():116395. PubMed ID: 35331976
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I
Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
[TBL] [Abstract][Full Text] [Related]
5. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
[TBL] [Abstract][Full Text] [Related]
6. Treatment of central giant cell granuloma in children with denosumab.
Choe M; Smith V; Okcu MF; Wulff J; Gruner S; Huisman TAGM; Venkatramani R
Pediatr Blood Cancer; 2021 Mar; 68(3):e28778. PubMed ID: 33089644
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.
Uday S; Gaston CL; Rogers L; Parry M; Joffe J; Pearson J; Sutton D; Grimer R; Högler W
J Clin Endocrinol Metab; 2018 Feb; 103(2):596-603. PubMed ID: 29211870
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
9. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.
Lipplaa A; Dijkstra S; Gelderblom H
Curr Opin Oncol; 2019 Jul; 31(4):329-335. PubMed ID: 30844887
[TBL] [Abstract][Full Text] [Related]
10. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
Hindiskere S; Errani C; Doddarangappa S; Ramaswamy V; Rai M; Chinder PS
Clin Orthop Relat Res; 2020 Nov; 478(11):2522-2533. PubMed ID: 32401001
[TBL] [Abstract][Full Text] [Related]
11. Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort.
Boye K; Jebsen NL; Zaikova O; Knobel H; Løndalen AM; Trovik CS; Monge OR; Hall KS
Acta Oncol; 2017 Mar; 56(3):479-483. PubMed ID: 28105885
[TBL] [Abstract][Full Text] [Related]
12. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
[TBL] [Abstract][Full Text] [Related]
13. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
[TBL] [Abstract][Full Text] [Related]
14. Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications.
Jiang CY; Zhao L; Schuetze SM; Chugh R
Oncologist; 2022 Jul; 27(7):595-599. PubMed ID: 35589095
[TBL] [Abstract][Full Text] [Related]
15. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
16. Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study.
Lipplaa A; Schreuder WH; Pichardo SEC; Gelderblom H
Oncologist; 2023 Nov; 28(11):1005-e1104. PubMed ID: 37449658
[TBL] [Abstract][Full Text] [Related]
17. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
[TBL] [Abstract][Full Text] [Related]
18. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
Rutkowski P; Ferrari S; Grimer RJ; Stalley PD; Dijkstra SP; Pienkowski A; Vaz G; Wunder JS; Seeger LL; Feng A; Roberts ZJ; Bach BA
Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
[TBL] [Abstract][Full Text] [Related]
19. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
Reddy K; Ramirez L; Kukreja K; Venkatramani R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
[TBL] [Abstract][Full Text] [Related]
20. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.
Raimondi A; Simeone N; Guzzo M; Maniezzo M; Collini P; Morosi C; Greco FG; Frezza AM; Casali PG; Stacchiotti S
ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32661185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
